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Abstract
The receptor tyrosine kinase c-Met, its ligand HGF, and components of the downstream sig-
nalling pathway, have all been implicated in the pathogenesis of myeloma, both as modula-
tors of plasma cell proliferation and as agents driving osteoclast differentiation and
osteoblast inhibition thus, all these contribute substantially to the bone destruction typically
caused by myeloma. Patients with elevated levels of HGF have a poor prognosis, therefore,
targeting these entities in such patients may be of substantial benefit. We hypothesized that
ARQ-197 (Tivantinib), a small molecule c-Met inhibitor, would reduce myeloma cell growth
and prevent myeloma-associated bone disease in a murine model. In vitro we assessed the
effects of ARQ-197 on myeloma cell proliferation, cytotoxicity and c-Met protein expression
in human myeloma cell lines. In vivo we injected NOD/SCID-γmice with PBS (non-tumour
bearing) or JJN3 cells and treated them with either ARQ-197 or vehicle. In vitro exposure of
JJN3, U266 or NCI-H929 cells to ARQ-197 resulted in a significant inhibition of cell prolifera-
tion and an induction of cell death by necrosis, probably caused by significantly reduced lev-
els of phosphorylated c-Met. In vivo ARQ-197 treatment of JJN3 tumour-bearing mice
resulted in a significant reduction in tumour burden, tumour cell proliferation, bone lesion
number, trabecular bone loss and prevented significant decreases in the bone formation
rate on the cortico-endosteal bone surface compared to the vehicle group. However, no sig-
nificant differences on bone parameters were observed in non-tumour mice treated with
ARQ-197 compared to vehicle, implying that in tumour-bearing mice the effects of ARQ-197
on bone cells was indirect. In summary, these res ults suggest that ARQ-197 could be a
promising therapeutic in myeloma patients, leading to both a reduction in tumour burden
and an inhibition of myeloma-induced bone disease.
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Introduction
Multiple myeloma (MM) is a cancer of differentiated B-cells, characterised by the accumulation
of malignant plasma cells (MPCs) in the bone marrow. Common clinical manifestations include
bone marrow failure leading to anaemia, impaired immunity and thrombocytopaenia, renal
failure and a destructive bone disease caused by the disruption of normal bone remodelling,
stimulation of osteoclastic bone resorption and inhibition of osteoblastic bone formation. Mye-
loma bone disease is characterised by hypercalcaemia, focal lytic lesions leading to pathological
fractures, severe pain and functional deficit. Although patient survival has improved recently
with the use of immunomodulatory agents, e.g. thalidomide and its analogues [1–5], protea-
some inhibitors such as bortezomib [6–7] and carfilzomib [8–9], and the recent introduction of
monoclonal antibodies targeting key myeloma antigens (daratumumab and elotuzumab) [10–
11], the majority of patients still develop refractory disease and drug resistance [12]. Due to this,
MM remains a predominantly incurable disease with patients having a median survival time of
only 7 to 8 years [13]. This necessitates the need to identify new targets for drug development to
reduce the tumour load and prevent further tumour-induced bone disease.
One potential group of targets for drug development are the receptor tyrosine kinases
(RTKs). RTKs are transmembrane proteins that play an important role in mammalian cell pro-
cesses such as cell growth, differentiation and apoptosis. Although RTKs are important in nor-
mal cell physiology and are tightly regulated, dysregulation of certain RTKs by mutation or
gene rearrangement have been implicated as causative factors in the development and progres-
sion of many types of cancer [14]. The development of therapeutic agents, including low
molecular weight drugs and small molecule inhibitors (SMIs) that target various RTKs, have
become more prevalent, with many in various phases of clinical development [15]. In MM
numerous SMIs to RTKs have been developed, many of them targeting the RTK vascular
endothelial growth factor receptor. These inhibitors, when used in vivo, have been shown to
inhibit myeloma cell proliferation, migration and survival [16–17]. However, the effect of
these inhibitors on myeloma bone disease has not been thoroughly investigated.
The RTK c-Met, its natural ligand hepatocyte growth factor (HGF) and their signalling
pathway (HGF/c-Met) have been implicated in the pathogenesis of MM [18–19]. HGF is
expressed in human MM cell lines, promoting their growth and migration, and by freshly
extracted MPCs from patient bone marrow biopsies [18–19]. HGF binds to c-Met and induces
phosphorylation which leads to stimulation of cell proliferation and migration. HGF levels
have been found to be elevated in the serum of myeloma patients compared to healthy
matched controls, and this has correlated with a poor prognosis [20–22]. HGF has also been
implicated in the pathogenesis of bone disease [23]. These authors identified HGF production
by osteoclasts and expression of the HGF receptor by both osteoclasts and osteoblasts. These
data suggested HGF mediated autocrine regulation of osteoclasts and paracrine regulation of
osteoblasts and that HGF therefore acted as a coupling factor between osteoclast and osteoblast
activity. Subsequently, a number of studies noted expression of HGF by myeloma cell lines
and purified primary myeloma cells [19–20]. HGF has also been shown to inhibit BMP-
induced expression of alkaline phosphatase in human mesenchymal stem cells and the murine
osteoblast pre-cursor cell line C2C12 [24].
All the biological effects of HGF are mediated by c-Met and both have been found to be
expressed by MPCs, again implying an autocrine loop [18,25]. Immunohistochemical staining
of bone samples from myeloma patients showed concomitant expression of HGF and c-Met in
MPCs. In addition, phosphorylated c-Met was observed, further demonstrating the HGF/c-
Met system is active in patients with MM, and therefore this pathway could be an attractive
target for novel therapeutics [26–27].
Inhibition of c-Met prevents myeloma-induced bone disease
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Numerous approaches have been utilised to inhibit HGF/c-Met signalling. In MM a small
number of c-Met inhibitors have been investigated in vitro and in vivo. MP-470 (Amuvatanib)
showed growth inhibition in the U226 human myeloma cell line and tumoricidal activity in
primary MPCs without affecting normal healthy cells [28]. SU11274 inhibited myeloma cell
proliferation and migration in vitro [25,29]. ARQ-197 (Tivantinib), a non-ATP-competitive c-
Met inhibitor, induced apoptosis by >50% in 12 human myeloma cell lines, including those
resistant to standard chemotherapy, and in a murine xenograft model of MM it was shown to
reduce a subcutaneous tumour [30]. To date the effects of ARQ-197 on myeloma induced-
bone disease have not been investigated.
In this article, we demonstrate the efficacy of ARQ-197 on the JJN3, U266 and NCI-H929
human myeloma cell lines in vitro and its effects in vivo on tumour burden and bone disease in
the JJN3-NSG murine model of MM.
Materials and methods
Ethics statement
All procedures involving animals were approved by the Home Office (PPL 70/8799) and the
University of Sheffield’s Animal Ethics Committee. Patient samples were acquired with appro-
priate ethical permission (REC reference: 05/Q2305/96).
Relative HGF gene expression from human myeloma cell lines and primary
sample
The myeloma cell lines JJN3, NCI-H929 and RPMI-8226 were purchased from DSMZ (Ger-
many). U266 cells were purchased from LGC Standards (UK) and XG-1 cells were kindly
provided by John Shaughnessy, Little Rock, USA. All cell lines were authenticated using poly-
morphic short tandem repeat (STR) loci (using the COG Cell Line and Xenograft STR Data-
base, 8 STR loci and Amelogenin) and screened for Mycoplasma. All cell lines were seeded in
12 well plates at 2x105 in 4 ml RPMI-1640 complete medium. After 48 h incubation, 2 ml used
media was removed and replaced with 2 ml fresh media (containing 10% FCS, 1% penicillin/
streptomycin, 100 U/100 μg/ml, 1% non-essential amino acids and 1% sodium pyruvate, 1 mM)
at 37˚C in 5% CO2. After 96 h, all cells were harvested. A bone marrow aspirate was taken from
a healthy donor and primary plasma cells isolated using magnetic cell sorting with CD138+
Microbeads (Milenyl Biotec, Bisley, UK).Total RNA was extracted from the human myeloma
and primary plasma cells using an ALLPrep isolation kit (Qiagen, Manchester, UK) followed by
cDNA first strand synthesis using a Miscript RT kit (Qiagen). Real-time PCR was conducted
using a human TaqMan1 assay for HGF (Applied Biosystems, CA, USA), detected with ABI
Prism 7900HT sequence detection system and SDS software (Life Technologies, Paisley, UK).
Data were analysed using the 2 (-Delta Delta C(T)) method [31] and relative expression com-
pared to a housekeeping gene (human GAPDH, Applied Biosystems).
Protein expression of c-Met and phosphorylated c-Met from human
myeloma cell lines
JJN3, NCI-H929, RPMI-8226, U266 and XG-1 cells were seeded in 12 well plates at 2x105 in 4
ml RPMI-1640 complete medium. After 48 h incubation, 2 ml used media was removed and
replaced with 2 ml fresh media. After a further 48 h, cells were harvested, pelleted (400 x g for
10 min) and resuspended in 100 μl RIPA lysis buffer (Sigma-Aldrich) containing phosphatase
and protease inhibitors (1% v/v, Sigma-Aldrich). After 30 min on ice with agitation, the cell
debris were pelleted at 16,000 x g for 15 min at 4˚C and the supernatant containing proteins
Inhibition of c-Met prevents myeloma-induced bone disease
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stored at -20˚C until further processing. Protein samples (100 μl) were mixed with 100 μl
Laemmli sample buffer (Bio-Rad, Hemel Hempstead, UK) supplemented with 5% 2-Mercap-
toethanol (Sigma Aldrich) and heated for 5 min at 95˚C. Samples (20 μg total protein per lane)
were separated by SDS-PAGE on an 8% gel (100 v for 120 min) followed by electrophoretic
transfer to a 0.45 μm PVDF transfer membrane (Millipore, Cork, IRL) using standard condi-
tions [32]. The membrane was blocked with 5% BSA in TBS-Tween 0.05% for 1 h. The mem-
brane was cut into strips and incubated overnight (4˚C) with antibodies against c-Met
(EP1454Y), phosphorylated c-Met (Tyr 1234/1235) and GAPDH as a housekeeper (Abcam).
After a further 1 h incubation with a peroxidase-conjugated goat anti-rabbit secondary anti-
body (Dako, Stockport, UK), the membrane was pieced together and detection carried out
with chemiluminescence (Bio-Rad, Hemel Hempstead, UK) and a ChemiDoc imaging system
(Bio-Rad). Relative density was acquired with JJN3 compared against the other cell lines and
all densities normalised against GAPDH.
Cell proliferation and induced cell death of human myeloma cell lines after
ARQ-197 treatment
JJN3, U266 and NCI-H929 cells were seeded in triplicate in 96 well plates at 104 cells per well
in 200 μl RPMI-1640 complete medium. After 48 h (start of exponential growth phase) 100 μl
of used media was removed and replaced with 100 μl of fresh media containing concentrations
of ARQ-197 (Stratech, Newmarket, UK) ranging from 0.1563 to 5 μM and control media con-
taining DMSO. After a 48 h incubation, 20 μl of alamarBlue1 (ThermoFisher Scientific,
Altrincham, UK) was added to each well. After a further 4 h incubation, fluorescence (excita-
tion-570 nm, emission-600 nm) was quantified using a Spectramax M5 plate reader (Molecu-
lar Devices, CA, US) and percentage reduction in cell proliferation was measured [33]. For
measuring the percentage induced cell death, cells were seeded and treated (as above) and a
trypan blue (Sigma-Aldrich, Gillingham, UK) exclusion count was performed [34].
Flow cytometric analysis of induced cell death of human myeloma cell lines
after ARQ-197 treatment
JJN3, U266 and NCI-H929 cells were seeded in 24 well plates at 105 cells per well in 2 ml
RPMI-1640 complete medium. After 48, 1 ml of used media was removed and replaced with 1
ml of fresh media containing 0.3125, 1.25 and 5 μM concentrations of ARQ-197 and control
media containing DMSO. After a 48 h incubation, cells were stained with Annexin V-APC
and propidium iodide (Affymetrix, CA, USA) and apoptosis/necrosis analysed by flow cytom-
etry using a FACS calibur with Cell quest software (BD Biosciences, IL, USA) and quantifica-
tion carried out using FlowJoTM software (BD Biosciences).
Protein expression of c-Met and phosphorylated c-Met from JJN3 human
myeloma cells after ARQ-197 treatment
JJN3 cells were seeded in 12 well plates at 2x105 in 4 ml RPMI-1640 complete medium. After
48 h incubation, 2 ml used media was removed and replaced with 2 ml fresh media. Contain-
ing either DMSO (control) or 1 μM ARQ-197. After 24 h, 48 h and 72 h cells were harvested
and immunoblotted for c-Met and phospho-c-Met as described above.
Osteoclast isolation and differentiation
Bone marrow from murine tibiae was flushed with PBS and cultured in αMEM media with
10% FCS (37˚C, l 5% CO2) for 24 h to allow stromal cells to attach. After 24 h the cells were
Inhibition of c-Met prevents myeloma-induced bone disease
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harvested and seeded onto sterile dentine discs (sterilised in an ultrasound bath and pre-
soaked in αMEM media) in 96 well plates at 0.5 x 106 cells per well in 100 μl αMEM media
with 10% FCS, recombinant mouse M-CSF (150 μg/ml, R and D Systems, Oxford, UK) and
recombinant mouse RANK-L (30 μg/ml, R and D Systems). After 24 h, the cells were washed
(4 times with media excluding M-CSF and RANK-L) and then 200 μl fresh media containing
M-CSF/RANK-L added to each well. After a further 48 h, the used media was removed and
fresh media added (containing M-CSF/RANK-L) with either DMSO (N = 2), 1 μM ARQ-197
(N = 2) or 1 μM ARQ-197 with 50 ng recombinant mouse HGF (R and D systems) (N = 2).
The cells were treated 3 times a week for 2 weeks. After 2 weeks the discs were fixed in 10%
buffered formalin overnight and stained for tartrate-resistant acid phosphatase (TRAP) [35].
Images were taken under light microscopy.
Treatment of JJN3 tumour-bearing and non-tumour bearing NSG mice
with ARQ-197
Female NOD/SCID-γ mice (7–8 weeks old) were randomised into 3 groups (N = 8/group).
Numbers per group were based on power calculations from previous studies [36]. All animals
were housed in cages in pathogen free conditions and were healthy at the start of the study.
Group 1 was a non-tumour bearing control group (naïve). Groups 2 and 3 were injected via
the tail vein with 106 JJN3 cells. From 7 to 21 days post tumour cell injection mice were treated
5 times a week by oral gavage with 100 μl 1% methylcellulose (naive, group 1 and JJN3 tumour
control, group 2) or 200 mg/kg/day ARQ-197 (JJN3+ARQ-197, group 3). Calcein and alizarin
complexone (both at 30 mg/kg in 0.2% sodium bicarbonate, Sigma) were given by intraperito-
neal injection at the onset of treatment and then every 4 days. A supplementary study was car-
ried out with non-tumour bearing mice treated with vehicle (N = 5) or 200 mg/kg/day ARQ-
197 (N = 4) as above regimen. All treatments were carried out at the same time each day. Ani-
mals were monitored daily for any adverse effects. At the first signs of morbidity (after 3
weeks) all animals were anesthetized (100% w/v isoflurane & 2% oxygen by inhalation) for car-
diac bleeding and sacrificed by cervical dislocation. Bone disease and tumour burden were
assessed as described below.
Micro-CT analysis of bone disease
Right tibiae and vertebrae (L3) were fixed in 10% formalin and scanned using a SkyScan 1272
(Bruker, Kontich, Belgium) as previously described [37]. All the measurements above followed
standard guidelines [38]. Osteolytic lesions (Lesions No) were quantified using ImageJ soft-
ware (v.1.47t, NIH, USA) as described previously [39].
Histological and histomorphometric analyses of tumour burden,
osteoblasts and osteoclasts
After micro-CT (μCT) analysis, the right tibiae were decalcified in EDTA at room temperature
for 4 weeks, embedded longitudinally in wax and sectioned at two levels 50 um apart. 3 μm sec-
tions were stained with H/E or TRAP for tumour burden and osteoclast/osteoblast quantifica-
tion respectively. Tumour burden was quantified on Haematoxylin stained sections using
Osteomeasure software (Osteometrics, GA, USA) and under light microscopy using a BX53
microscope (Olympus, Southend on Sea, UK). The percentage area of JJN3 cells was deter-
mined in an area of marrow measuring 1.8 mm2 and with an offset of 0.25 mm from the
growth plate. Osteoblast and osteoclast identification on the TRAP stained sections was carried
out as previously described [37]. Left tibiae were fixed in 70% IMS, dehydrated through graded
Inhibition of c-Met prevents myeloma-induced bone disease
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alcohols (80% - 100%) and embedded longitudinally in LR White medium resin (TAAB Labo-
ratories, Aldermaston, UK). 10 μm sections were taken and the last pair of calcein/alizarin
complexone labels analysed as previously described [37]. All the histomorphometric indices
used have been standardised [40].
Immunohistochemical analysis of cell proliferation and necrosis
Wax sections (3 μm) of the right tibiae were dewaxed in xylene, rehydrated through graded
alcohols, and heat mediated antigen retrieval carried out using a water bath at 80˚C for 30 min
with citrate buffer pH6 (Abcam, Cambridge, UK). Endogenous peroxidase was blocked with
3% hydrogen peroxide for 30 min at room temperature (RT) and blocked in 1% casein in
PBS-Tween 0.1% (TBST) for 30 min at RT. Monoclonal primary antibodies anti-human Ki-67
or anti-human Annexin V (Abcam) were added to the sections at a dilution of 1:100 in 1%
casein and incubated overnight at 4˚C. After 3 washes in TBST, the sections were treated with
biotinylated goat anti-rabbit IgG secondary antibody (Vector Laboratories, Peterborough,
UK) at 1:200 in 1% casein for 1 hr at RT. Sections were then treated with an ABC kit (Vector
laboratories) for 20 min at RT and the bound antibody detected with DAB chromagen (Vector
Laboratories) for 10 min at RT. The sections were washed in tap water, counter stained in
Gills haematoxylin for 20 sec, dehydrated through graded alcohols, treated with xylene and
mounted. The number of Ki-67 and Annexin V positive cells in a 250 x 250 μm area of tumour
was quantified under light microscopy using the Osteomeasure system.
Statistical analysis
All data sets were analysed using GraphPad Prism version 6.05 (CA, USA). Normalisation was
assessed using a D’Agostino-Pearson test and subsequent parametric or non-parametric statis-
tical tests used. If the normalisation test could not be carried out, a normal distribution was
assumed. Comparisons between groups were compared using either a Student’s T-test or a
One-way ANOVA with a Bonferroni post- hoc test where p<0.05 was considered significant.
Data are expressed as mean ± SD.
Results
To find a suitable human myeloma cell line for in vitro assays and an in vivo study, we quanti-
fied the gene expression of HGF in 5 human myeloma cell lines and healthy plasma cells by
real-time PCR, relative to the housekeeping gene GAPDH. JJN3 cells showed a significantly
higher gene expression of HGF (p<0.0001) compared to NCI-H929, U266, XG1, RPMI-8226
cell lines and healthy human plasma cells (Fig 1A). Of the five human MM cell lines, all
showed protein expression of basal c-Met with U266 cells giving the highest relative density
(RD) of 1.51, with JJN3, XG-1, RPMI-8226 and NCI-H929 showing RD values of 1, 0.98, 0.99
and 1.22 respectively (Fig 1B). All of the cell lines except XG-1 cells expressed phospho-c-Met
with JJN3 cells producing the highest level of expression (Relative density of 1, with U266,
RPMI-8226 and NCI-H929 showing RD values of 0.82, 0.81 and 0.71 respectively (Fig 1B).
Treatment of JJN3, U266 and NCI-H929 cells with ARQ-197 inhibits cell
proliferation, induced cell death, increases cell necrosis and reduces c-Met
and phosphorylated c-Met protein expression
To test the efficacy of ARQ-197 in vitro, we added varying concentrations to JJN3, U266
and NCI-H929 cells and incubated them for 48 h to assess cell proliferation and cell death
(Fig 2A). Compared to the DMSO control, all concentrations of ARQ-197 except 0.1563 μM
Inhibition of c-Met prevents myeloma-induced bone disease
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significantly reduced proliferation in all three cell lines. ARQ-197 at 0.3125 μM reduced prolif-
eration by at least 21.5% (p<0.01) in JJN3 cells, 63% in U266 cells and 15.2% in NCI-H929
cells. Concentrations between 0.625 to 5 μM reduced proliferation by up to 67% (p<0.0001) in
JJN3 cells, up to 77% (p<0.0001) in U226 cells and up to 89% (p<0.0001) in NCI-H929 cells.
Next we assessed induced cell death of JJN3, U266 and NCI-H929 cells by ARQ-197 treat-
ment using trypan blue exclusion counts (Fig 2B). Compared to the DMSO control (11%,
4.1% and 4.7% cell death respectively), ARQ-197 at 0.1563 μM and 0.3125 μM had no signifi-
cant effects in all three cell lines. Concentrations of 0.625 to 2.5 μM initiated cell death ranging
from 38% - 44% (p<0.001-p<0.0001) for JJN3 cells, 39%- 50% (p<0.001-p<0.0001) for U266
cells and 28%-41% (p<0.001-p<0.0001) for NCI-H929 cells. At a concentration of 5 μM there
was a more noticeable increase in cell death at 61% (p<0.0001) for JJN3 cells, 64% (p<0.0001)
for U266 cells and 69% (p<0.0001) for NCI-H929 cells.
AnnexinV/PI stained JJN3 cells treated with ARQ-197 were analysed by flow cytometry to
assess the quantity of viable, apoptotic and necrotic cells (Fig 2C). The majority of untreated
JJN3 cells (Fig 2Ci) were viable (90.1%), with only 2.55% necrotic and 4.36% apoptotic. ARQ-
197 at 0.3125 μM (Fig 2Cii) reduced the viability of JJN3 cells to 13.6% with the majority of
cells necrotic (70.8%). Treatment with 1.25 μM (Fig 2Ciii) and 5 μM (Fig 2Civ) ARQ-197
showed the same levels of necrosis (71.3%). Increasing concentrations of ARQ-197 produced
slightly higher numbers of apoptotic cells (12.8–18.8%). U266 and NCI-H929 cells showed
similar results (not shown).
Finally, we measured c-Met and phosphorylated c-Met protein expression using immuno-
blotting by treating JJN3 cells with ARQ-197 at 1 μM for varying periods of time (24 h, 48 h
and 72 h, Fig 2D). Compared to media controls, ARQ-197 at 1 μM visibly reduced both c-Met
and phosphorylated c-Met protein expression at 24 h and almost completely inhibited expres-
sion at 48 h and 72 h.
ARQ-197 treatment inhibits the growth of osteoclasts
The effect of ARQ-197 (1 μM) on osteoclasts seeded onto dentine discs was assessed after 14
days treatment. Compared to media controls which showed visible TRAP stained osteoclasts
and erosion pits on the dentine surface (Fig 2E), treatment with ARQ-197 in the presence or
Fig 1. JJN3 human myeloma cells exhibited higher HGF gene expression compared to other human myeloma cell lines and healthy plasma cells
and a higher phospho-c-Met protein level than other human myeloma cell lines. (A) Relative HGF gene expression of human myeloma cell lines
JJN3, NCIH-H929, U226, XG-1 and RPMI-8226 and healthy human plasma cells (control). All data displayed as mean ± SD and analysed using a
normal one-way ANOVA, where significance is indicated by P<0.0001. (B) Phospho-c-Met and total c-Met protein levels in human myeloma
cells.
https://doi.org/10.1371/journal.pone.0199517.g001
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Fig 2. ARQ-197 inhibits cell proliferation, induces cell death by necrosis and reduces protein expression of
phospho-c-Met and c-Met. (A) JJN3, U266 and NCI-H929 cells were incubated with control media containing DMSO
or ARQ-197 at 0.1563, 0.3125, 0.625, 1.25, 2.50 or 5 μM for 48 h. Cell proliferation was measured compared to DMSO
control. (B) JJN3, U266 and NCI-H929 cells were incubated with control media containing DMSO or ARQ-197 at
0.1563, 0.3125, 0.625, 1.25, 2.50 or 5 μM for 48 h and counted using trypan blue exclusion and the percentage cell death
calculated. All data displayed as mean ± SD and analysed using a normal one-way ANOVA, where significance is
indicated by P<0.01, P<0.001 or P<0.0001. (C) JJN3 cells were treated with control media containing
DMSO (i) or ARQ-197 at 0.3125 (ii), 1.25 (iii) or 5 μM (iv) and then stained with annexin V/PI before flow cytometric
analysis. In the flow cytrometry plots, Q1 relates to dead cells, Q2 necrotic, Q3 apoptotic and Q4 viable cells. (D) JJN3
cells were treated with control media containing DMSO or 1 μM ARQ-197 for 24 h, 48 h and 72 h and immunoblotted
with an anti-phospho-c-Met antibody and an anti-c-Met antibody. (E) Representative images of osteoclasts treated
with either control media containing DMSO, ARQ-197 1 μM or ARQ-197 1 μM with HGF 50 ng.
https://doi.org/10.1371/journal.pone.0199517.g002
Inhibition of c-Met prevents myeloma-induced bone disease
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absence of HGF prevented the growth of any osteoclasts and subsequent erosion pits as visual-
ised under light microscopy (Fig 2E).
ARQ-197 treatment reduces tumour burden and Ki-67 positive cells in
JJN3-bearing NSG mice
The percentage infiltration of JJN3 cells in the bone marrow of tumour-bearing mice com-
pared to ARQ-197 treated tumour-bearing mice was analysed by histomorphometry (Fig 3A).
Vehicle treated tumour-bearing control mice had 96±4.9% tumour infiltration of the bone
marrow compared to 55±20% infiltration of tumour-bearing mice treated with ARQ-197, giv-
ing an overall tumour percentage reduction of approximately 43% (p<0.001, Fig 3D).
The number of Ki-67 positive tumour cells in the bone marrow was assessed by immuno-
histochemical staining (Fig 3B). Treatment of tumour-bearing mice with ARQ-197 signifi-
cantly reduced the number of Ki-67 positive cells compared to tumour bearing mice (588±121
and 899±134 respectively, p<0.001, Fig 3E).
The number of Annexin V positive tumour cells in the bone marrow was also assessed by
immunohistochemical staining (Fig 3C). There were no significant differences in Annexin V
Fig 3. ARQ-197 reduces tumour burden and tumour cell proliferation but does not induce cell death by necrosis in JJN3 tumour-
bearing mice. (A) Representative images of histological sections stained by Haematoxylin for tumour burden, (B) immunohistological
staining by anti-Ki-67 or (C) anti-Annexin V. All scale bars = 100 μm. Histomorphometric analysis of (D) tumour burden, (E) Ki-67
and (F) Annexin V on tibiae from JJN3 tumour-bearing mice treated with either vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197). All data
displayed as mean ± SD and analysed using an unpaired t-test, where significance is indicated by P<0.001.
https://doi.org/10.1371/journal.pone.0199517.g003
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positive cells between ARQ-197 treated tumour-bearing mice and tumour-bearing mice (85±
29 and 77±36 respectively, Fig 3F).
ARQ-197 prevents tumour-induced bone disease in JJN3-NSG mice
Micro-CT analysis of the tibiae and vertebrae from vehicle treated tumour-bearing mice
revealed evidence of osteolytic lesions and a significant loss of trabecular bone compared to
naïve mice (non-tumour controls) (Fig 4A–4C). In vehicle treated JJN3 tumour-bearing mice,
there were visible lesions present in the tibiae (Fig 4A) compared to no visible lesions in either
the naïve or tumour-bearing mice treated with ARQ-197. Automated lesion counts using 2-D
software showed a significant increase in lesions in the tumour-bearing mice compared to
naïve mice (51.6±8.0 and 3.6±1.2 respectively, p<0.0001, Fig 4D). Tumour-bearing mice
treated with ARQ-197 showed a significantly reduced number of lesions compared with
tumour-bearing mice (9.3±4.3 and 51.6±8.0 respectively, p<0.0001).
Percentage trabecular bone fraction (BV/TV, %) was significantly reduced in the tibiae of
vehicle treated tumour-bearing mice compared with the naïve mice (3.0%±1.3 and 7.4%±2.2
respectively, p<0.001, Fig 4E). Tumour-bearing mice treated with ARQ-197 showed increased
BV/TV compared with vehicle treated tumour-bearing mice (6.3%±1.6 and 3.0%±1.3 respec-
tively, p<0.01, Fig 4E). BV/TV was also significantly reduced in the vertebrae of vehicle treated
tumour-bearing mice compared with the naïve mice (7.3%±2.2 and 13.4%±1.9 respectively,
p<0.0001, Fig 4C and 4F). Tumour-bearing mice treated with ARQ-197 showed increased ver-
tebral BV/TV compared with vehicle treated tumour-bearing mice (10.2%±1.8 and 7.3%±2.2
Fig 4. ARQ-197 reduces the number of osteolytic lesions and prevents the loss of trabecular bone in JJN3 tumour-
bearing mice. (A) Representative μCT 3D and (B) cross-sectional images of tibiae or (C) vertebrae (L3) from naïve
mice (Naïve) and tumour-bearing mice treated with vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197). (D) Lesion counts
(Lesions NO) and (E) trabecular bone fraction (BV/TV %) analysed by μCT of the tibiae or (F) vertebrae (L3) from
naïve mice (Naïve) and tumour-bearing mice treated with vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197). All data
displayed as mean ± SD and analysed using a normal one-way ANOVA, where significance is indicated by P<0.05,
P<0.01, P<0.001 or P<0.0001.
https://doi.org/10.1371/journal.pone.0199517.g004
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respectively, p<0.05, Fig 4F). There were no significant differences in tibial or vertebral BV/
TV between naïve mice and naïve mice treated with ARQ-197 (S1 Fig).
ARQ-197 treatment reduces osteoclastic bone resorption in tumour-
bearing mice
Histomorphometric assessment of the cortico-endosteal surface of the tibiae showed differ-
ences in TRAP positive osteoclasts (Fig 5A). Analysis of the cortico-endosteal surfaces showed
a significant increase in osteoclast number in tumour-bearing mice compared to naïve mice
(5.8±3.1 and 1.5±1.3 respectively, p<0.01, Fig 5B). Treatment of tumour-bearing mice with
ARQ-197 reduced osteoclast number compared to tumour-bearing mice (4.0±1.8 and 5.8±3.1
respectively, Fig 5B), although this was not significant. Percentage surface occupied by osteo-
clasts of the tumour-bearing mice compared to naïve mice showed a significant increase (23.3
±13.4% and 8.2±12.0% respectively, p<0.05, Fig 5C). Treatment of tumour-bearing mice with
ARQ-197 reduced percentage surface occupied by osteoclasts compared to tumour-bearing
mice (13.20±6.3 and 23.3±13.4% respectively, Fig 5C), although this was not significant. There
were no significant differences in osteoclastic bone resorption between naïve mice and naïve
mice treated with ARQ-197 (S2 Fig).
Fig 5. ARQ-197 reduces osteoclastic bone resorption on cortico-endosteal surfaces of the tibiae from JJN3 tumour-
bearing mice. (A) Representative images of TRAP positive osteoclasts (stained red) on the cortico-endosteal surface of
tibiae from naïve mice (Naïve) and tumour-bearing mice treated with vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197) (scale
bar = 50 μm). (B) Histomorphometric analysis of the number of TRAP positive osteoclasts per mm cortico-endosteal bone
(N.Oc/BS,mm) and (C) the percentage coverage of TRAP positive osteoclasts on the cortico-endosteal bone (Oc.S/BS (%)
from naive mice (Naïve) and tumour-bearing mice treated with vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197). All data
displayed as mean ± SD and analysed using a normal one-way ANOVA, where significance is indicated by P<0.05 or
P<0.01.
https://doi.org/10.1371/journal.pone.0199517.g005
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ARQ-197 treatment inhibits loss of osteoblasts in tumour-bearing mice
Histomorphometric assessment of the cortico-endosteal surface (Fig 6A) of tibiae showed oste-
oblasts identified by their unique morphology. Analysis of the cortico-endosteal surfaces
showed a highly significant reduction in osteoblast number in vehicle treated tumour-bearing
mice compared to naïve mice (0.1±0.3 and 41.7±8.6 respectively, p<0.0001, Fig 6B). Treatment
of tumour-bearing mice with ARQ-197 increased osteoblast number slightly compared to
tumour-bearing mice (6.6±8.7 and 0.1±0.3 respectively, Fig 6C), although this was not signifi-
cant. Percentage surface occupied by osteoblasts of the tumour bearing mice compared to naïve
mice showed a highly significant decrease (0.3±0.7% and 63.5±9.2% respectively, p<0.0001, Fig
6C). Treatment of tumour-bearing mice with ARQ-197 slightly increased percentage surface
occupied by osteoblasts compared to tumour-bearing mice (12.9±17.3 and 0.3±0.7% respec-
tively, Fig 6C), although this was not significant. There were no significant differences in osteo-
blast numbers between naïve mice and naïve mice treated with ARQ-197 (S3 Fig).
ARQ-197 treatment inhibits the loss of bone formation in tumour-bearing
mice
Histomorphometric assessment of the calcein and alizarin complexone labelling on the cor-
tico-endosteal surface allowed assessment of bone mineralisation (Fig 7A and 7B).
Fig 6. ARQ-197 inhibits osteoblast loss on the cortico-endosteal surfaces of the tibiae from JJN3 tumour-bearing mice.
(A) Representative images of osteoblasts on the cortico-endosteal surface of tibiae from naïve mice (Naïve) and tumour-
bearing mice treated with vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197) (scale bar = 50 μm). (B) Histomorphometric
analysis of the number of osteoblasts per mm cortico-endosteal bone (N.Ob/BS,mm) and (C) of the percentage coverage of
osteoblasts on the cortico-endosteal bone (Ob.S/BS (%) from naive mice (Naïve) and tumour-bearing mice treated with
vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197). All data displayed as mean ± SD and analysed using a normal one-way
ANOVA, where significance is indicated P<0.0001.
https://doi.org/10.1371/journal.pone.0199517.g006
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Mineralising surface, defined as the extent of bone surface actively mineralising, was signifi-
cantly reduced in tibiae of tumour-bearing mice compared to naïve mice (27.1±13.0% and
82.4±9.9% respectively, p<0.0001, Fig 7C). Treatment of tumour-bearing mice with ARQ-197
significantly increased the extent of mineralising surface compared to tumour-bearing mice
(54.5±13.5% and 27.1±13.0% respectively, p<0.001, Fig 7C). MAR, defined as distance
between the labels over time, was significantly reduced in tumour-bearing mice compared to
naïve mice (1.35±0.39 μm/d and 2.38±0.93 μm/d respectively, p<0.05, Fig 7D). Treatment of
tumour-bearing mice with ARQ-197 significantly increased MAR (2.38±0.9 μm/d and 1.35
±0.38 μm/d, p<0.05, Fig 7D). BFR was reduced in tumour-bearing mice compared to naïve
mice (0.35±0.16 mm2 x 10−3/mm/d and 2.17±0.80 mm2 x 10−3/mm/d respectively, p<0.0001,
Fig 7E). Treatment of tumour-bearing mice with ARQ-197 significantly increased BFR com-
pared to tumour-bearing mice (1.32±0.57 mm2 x 10−3/mm/d and 0.35±0.16 mm2 x 10−3/
mm/d, p<0.05, respectively, Fig 7E). There were no significant differences in mineralising
surface, MAR or bone formation between naïve mice and naïve mice treated with ARQ-197
(S4 Fig).
Fig 7. ARQ-197 inhibits bone formation loss on the cortico-endosteal surface of the tibiae from JJN3 tumour-bearing mice.
Representative images of bone formation on the, cortico-endosteal surfaces, (A) magnification x4 (scale bar = 500 μm) and (B)
magnification x20 (scale bar = 100 μm) of tibiae from naïve mice (Naïve) and tumour-bearing mice treated with vehicle (JJN3) or
ARQ-197 (JJN3+ARQ-197). Histomorphometric analysis of (C) the mineralising surface (MS, %) (D) the mineral apposition rate
(MAR, μm/day) and (E) the bone formation rate (BFR/BS, mm2 X 10−3/mm/day) on the cortico-endosteal bone surface of tibiae
from naive mice (Naïve) and tumour-bearing mice treated with vehicle (JJN3) or ARQ-197 (JJN3+ARQ-197). All data displayed as
mean ± SD and analysed using a normal one-way ANOVA, where significance is indicated by P<0.05, P<0.001 or
P<0.0001.
https://doi.org/10.1371/journal.pone.0199517.g007
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Discussion
MM is still predominately an incurable disease despite new therapies emerging [41]. The
HGF/c-Met pathway has been associated with the development of numerous solid tumours
[42] and has been implicated in the pathogenesis of MM with the discovery of an autocrine
loop [18,29] and the pathogenesis of myeloma bone disease. Several recent studies have previ-
ously indicated a vital role for HGF in the pathogenesis of MM. In the present work we sought
to assess the effect of ARQ-197, a specific c-Met inhibitor, on tumour burden and on bone dis-
ease in a xenograft model of MM. Numerous SMIs to c-Met have been tested in patients with
various tumour types in clinical trials [43]. ARQ-197 is a selective inhibitor of c-Met activity,
and is found to be non-ATP competitive, therefore retaining its effectiveness in cells [44]. The
efficacy of this SMI has been tested on a number of human cancer cell lines, including MM
[30, 45–46]. ARQ-197 has also been tested in clinical studies on numerous types of tumour
including MM [47–48]. However, the effect of ARQ-197 on myeloma-induced bone disease
has not yet been thoroughly assessed. Therefore, the aim of this work was to extensively assess
the effects of ARQ-197 in the JJN3-NSG xenograft model of MM [36], known to develop
severe bone disease, using a therapeutic approach, i.e. once tumour has been established. In
addition, we also assessed the anti-tumour effects of ARQ-197 on JJN3 cells both in vitro and
in vivo.
For in vitro and in vivo studies we wanted to select a suitable human MM cell line which
highly expressed both HGF and phospho-c-Met. Of the five human myeloma cell lines tested,
only JJN3 showed a significantly high HGF gene expression, supporting previous findings
[18]. All cell lines expressed basal c-Met protein and all but one also expressed constitutively
phosphorylated c-Met protein. Of these cell lines, JJN3 showed the highest protein expression
of phospho-c-Met which was in agreement with previous findings [18].
Utilising the myeloma cell lines JJN3, U266 and NCI-H929 we showed that ARQ-197
reduced cell proliferation and induced cell death in a dose-dependent manner in all three cell
lines, supporting previous data [30]. As the U266 cell line expressed low HGF gene expression
and the NCI-H929 no HGF gene expression, this suggests that the level of HGF expression
doesn’t affect the efficacy of ARQ-197 and the cytotoxic action of ARQ-197 may also be inde-
pendent of c-Met status as previously suggested [47]. Subsequent Annexin V/PI staining of
ARQ-197 treated JJN3 cells showed cell death as a result of necrosis rather than apoptosis,
which suggests ARQ-197 has a cytotoxic effect on JJN3 cells. Immunoblotting of JJN3 cell
lysates showed that treatment by ARQ-197 reduced phospho-c-Met (Y1234/1235) and c-Met
(EP1454Y) protein expression, consistent with previous findings using human myeloma cell
lines [30].
The effect of ARQ-197 treatment on osteoclasts in vitro was also assessed. After two weeks
treatment, there were no visible signs of osteoclasts or their activity as indicated by dentine
erosion. This indicates that osteoclasts in vitro are highly sensitive to the effects of ARQ-197,
either having a cytotoxic effect on osteoclasts or inhibiting proliferation by blocking c-Met
phosphorylation. The addition of HGF did not alter the effects of ARQ-197 on osteoclasts.
Next we assessed the effect of ARQ-197 in a xenograft model of MM, where NSG mice
were injected with human JJN3 cells, resulting in tumour infiltration of the bone marrow and
subsequent tumour growth and development of lytic bone disease. Treatment of tumour-bear-
ing mice with ARQ-197 resulted in a 43% reduction in tumour burden compared to those
treated with vehicle. Although this tumour reduction was significant, when JJN3 cells were
treated with ARQ-197 in vitro the reduction in cell proliferation was more pronounced. This
variance could arise from the tumour cells growing independent of c-Met signalling, suggest-
ing ARQ-197 would be less effective as hypothesised in a previous study [30]. Alternatively,
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the concentration of ARQ-197 in the bone marrow is maybe lower than in vitro. Therefore,
potentially higher or more frequent doses may be required to increase its anti-tumour effects
in vivo. Previous studies on the anti-tumour effects of ARQ-197 in murine xenograft models
have shown a reduction in tumour volume [30,45]. Similarly, the effects of ARQ-197 in
human clinical trials have been encouraging and have been shown to stabilise disease in some
patients [48–50]. Treatment of tumour-bearing mice with ARQ-197 resulted in a significantly
reduced number of Ki-67 positive tumour cells but had no effect on the number of Annexin V
positive tumour cells. This suggests that the reduction in tumour burden is as a consequence
of reduced tumour cell proliferation rather than cell death by necrosis.
The effect of ARQ-197 treatment on tumour-induced bone disease was next assessed.
Although the reduction in tumour burden was not as effective as expected, the effects on pre-
venting myeloma-induced bone disease in vivo were quite pronounced, especially in a murine
model of myeloma with aggressive disease and significant bone loss at the end stages [35].
Tumour-bearing mice treated with ARQ-197, compared to vehicle treated control mice,
resulted in an inhibition of tumour-induced bone loss of trabecular bone. Since JJN3 cells
secrete high levels of the osteoblast inhibitory factor HGF, a reduction in tumour volume may
prevent the development of bone disease. ARQ-197 treatment also significantly reduced the
number of osteolytic lesions compared to tumour-bearing mice. Histologically, tumour-bear-
ing mice had increased osteoclast numbers and decreased osteoblast numbers. This was proba-
bly as a direct effect of increased tumour volume in these mice, as myeloma tumour cells
secrete numerous osteoclast activating factors [51] and osteoblast inhibitory factors, including
HGF [52]. The reduced number of osteoclasts after ARQ-197 treatment may also have had a
role to play in the reduced tumour volume as osteoclasts have been found to stimulate prolifer-
ation and survival of MM cells [52]. This supports previous findings on human bone biopsies
from myeloma patients, which showed increased erosion depth with increased plasma cell
infiltration [53]. Treatment with ARQ-197 reduced tumour volume and therefore reduced
osteoclast numbers and increased osteoblast numbers. This effect was also reflected in the his-
tological assessment of bone formation. Tumour-bearing mice had reduced bone formation
compared to naïve mice and this reduction was inhibited after treatment with ARQ-197. We
also tested the efficacy of ARQ-197 on naïve mice with no tumour load. Compared to naïve
mice receiving no treatment, the ARQ-197 treated naïve mice showed no significant changes
in osteoblast number, osteoclast number or bone formation indices. Taken together, these
results imply that the inhibition of bone loss in tumour-bearing mice treated with ARQ-197 is
a consequence of tumour load reduction, and the prevention of HGF-induced inhibition of
osteoblasts, rather than a direct bone anabolic effect.
In summary, this study showed that ARQ-197 inhibited proliferation and induced death in
the JJN3 human myeloma cell line, and reduced tumour volume and inhibited bone loss in a
murine model of MM. Collectively, the findings generated in this study show ARQ-197 may
be an effective anti-tumour agent in the treatment of MM as others have shown, but more
importantly may also prevent myeloma-induced bone loss both as an indirect consequence of
reduced tumour load and as a direct consequence of blockade of HGF induced inhibition of
bone formation. Further studies are now required to evaluate its potential in combination
therapy, possibly in tandem with zoledronic acid and standard chemotherapy regimens.
Supporting information
S1 Fig. ARQ-197 does not affect trabecular bone fraction in naïve mice. (A) Trabecular
bone fraction (BV/TV %) of the tibiae or (B) vertebrae (L3) analysed by μCT from naïve mice
(Naïve) and naïve mice treated with ARQ-197 (Naïve + ARQ-197). All data displayed as
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mean ± SD and analysed using an unpaired t-test.
(TIF)
S2 Fig. ARQ-197 has no effect on osteoclastic bone resorption on cortico-endosteal sur-
faces of the tibiae from naïve mice. (A) Histomorphometric analysis of the number of TRAP
positive osteoclasts per mm cortico-endosteal bone (N.Oc/BS,mm) from naive mice (Naïve)
and naïve mice treated with ARQ-197 (Naïve + ARQ-197). (B) The percentage coverage of
TRAP positive osteoclasts on the cortico-endosteal bone (Oc.S/BS (%) from naive mice
(Naïve) and naive mice treated with ARQ-197 (Naive+ARQ-197). All data displayed as
mean ± SD and analysed using an unpaired t-test.
(TIF)
S3 Fig. ARQ-197 has no effect on osteoblasts on cortico-endosteal surfaces of the tibiae
from naïve mice. (A) Histomorphometric analysis of the number of osteoblasts per mm cor-
tico-endosteal bone (N.Ob/BS,mm) from naive mice (Naïve) and naïve mice treated with
ARQ-197 (Naïve + ARQ-197). (B) The percentage coverage of osteoblasts on the cortico-end-
osteal bone (Ob.S/BS (%) from naive mice (Naïve) and naive mice treated with ARQ-197
(Naive+ARQ-197). All data displayed as mean ± SD and analysed using an unpaired t-test.
(TIF)
S4 Fig. ARQ-197 has no effect on bone formation on the cortico-endosteal surface of the
tibiae from naïve mice. (A) Histomorphometric analysis of the mineralising surface (MS, %)
(B) the mineral apposition rate (MAR, μm/day) and (C) the bone formation rate (BFR/BS,
mm2 X 10−3/mm/day) on the cortico-endosteal bone surface of tibiae from naive mice (Naïve)
and naïve mice treated with ARQ-197 (Naïve + ARQ-197). All data displayed as mean ± SD
and analysed using an unpaired t-test.
(TIF)
S5 Fig. Full western blot from Fig 1.
(TIF)
S6 Fig. Full western blot of phospho c-Met from Fig 2.
(TIF)
S7 Fig. Full western blot of c-Met from Fig 2.
(TIF)
S1 Table. HGF expression data for myeloma cell lines in Fig 1.
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S3 Table. Cell death and cell proliferation data from Fig 2.
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